Clinical Trials Browser

INDUSTRY × toripalimab × 90 days × Clear all

NCT07481058 2026-03-18

A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06975293 2026-03-05

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Phase 1/2 Recruiting

188 enrolled

DermatologicGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT06457503 2026-03-02

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT06657144 2026-03-02

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

220 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Phase 3 Not yet recruiting

440 enrolled

Gynecologic

Cervical Cancer Metastatic

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Phase 1/2 Recruiting

228 enrolled

Other solid neoplasm

Solid Tumor

NCT06679985 2026-02-05

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase 2 Recruiting

72 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05518045 2026-02-04

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Phase 1/2 Active not recruiting

392 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

500 enrolled

Solid Cancer

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 3 Not yet recruiting

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Phase 1/2 Terminated

40 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Phase 2 Recruiting

90 enrolled

Genitourinary

Carcinoma, Transitional Cell